A Study Evaluating Safety and Efficacy of CBM.CD20 CAR-T(C-CAR066) in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy
Latest Information Update: 04 Oct 2024
At a glance
- Drugs JNJ 90009530 (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- 12 Dec 2023 Results assessing two-year follow-up results of C-CAR066, a novel anti-CD20 chimeric antigen receptor cell therapy (CAR-T) in relapsed or refractory (r/r) large B-Cell Lymphoma (LBCL) patients after failure of CD19 CAR-T therapy were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 22 Nov 2023 According to an AbelZeta media release, abstracts from this study have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Diego, California, and online from December 9 to 12, 2023.
- 22 Nov 2023 According to an AbelZeta media release, results from this study presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Diego, California, and online from December 9 to 12, 2023.